1 TITLE PAGE

- 2 Title: Neurofilament light and glial fibrillary acidic protein in mood and anxiety disorders: A
- 3 systematic review and meta-analysis

4 Authors (incl order)

Full name	Highest academic degree	Affiliation	Email address
Matthew JY Kang	MBBS, FRANZCP	Neuropsychiatry Centre, Royal Melbourne Hospital Department of Psychiatry,	Matthew.kang1@unimelb.edu.au
		University of Melbourne	
Jasleen Grewal	MBBS	Alfred Mental and Addiction Health, Alfred Health	Jas.grewal@alfred.org.au
		Neuropsychiatry Centre, Royal Melbourne Hospital	
Dhamidhu Eratne	MBChB, FRANZCP	Neuropsychiatry Centre, Royal Melbourne Hospital	deratne@unimelb.edu.au ORCiD: 0000-0002-3226-7645
		Department of Psychiatry, University of Melbourne	
Charles Malpas	PhD	Melbourne School of Psychological Sciences, University of Melbourne Department of Medicine, Royal Melbourne Hospital, University of Melbourne	charles.malpas@unimelb.edu.au
Wei-Hsuan Chiu	BBiomed(Hons), GDipPsych(Adv)	The Neuropsychiatry Centre, The Royal Melbourne Hospital	whchiu@student.unimelb.edu.au
		Department of Psychiatry, The University of Melbourne	ORC1D: 0000-0002-5066-2999
Kasper Katisko	MD, PhD	Institute of Clinical Medicine – Neurology, University of Eastern Finland, Kuopio, Finland	kasper.katisko@uef.fi
Eino Solje	MD, PhD	Institute of Clinical Medicine – Neurology, University of Eastern Finland, Kuopio, Finland	eino.solje@uef.fi

		Neuro Center – Neurology,	
		Kuopio University Hospital,	
		Kuopio, Finland	
Alexander F	MD, PhD	Department of Clinical	alexander.frizell_santillo@med.lu.se
Santillo		Sciences, Clinical Memory	
0000-0001-		Research Unit, Faculty of	
9717-0820		Medicine, Lund University,	
		Malmö, Sweden	
Philip B.	MBBS, MD	Discipline of Psychiatry &	phil.mitchell@unsw.edu.au
Mitchell		Mental Health, Faculty of	-
		Medicine and Health, UNSW,	
		Sydney	
Malcolm	MD,	Ramsay Clinic Albert Road &	mhopwood@unimelb.edu.au
Hopwood	FRANZCPsych	Department of Psychiatry,	-
-		University of Melbourne	
Dennis	MBBS,	Neuropsychiatry Centre, Royal	Dennis.Velakoulis@mh.org.au
Velakoulis	DMedSci	Melbourne Hospital	
		-	
		Department of Psychiatry,	
		University of Melbourne	

5

6 Corresponding Author

- 7 Dr. Matthew JY Kang
- 8 The Royal Melbourne Hospital Mental Health Services & Neuropsychiatry Centre
- 9 The RMH Elizabeth Street
- 10 635 Elizabeth Street | Melbourne 3000
- 11 P: 03 9138 2850 | F: 03 7024 7004 | M: 0437 631 101
- 12 Matthew.Kang@mh.org.au | thermh.org.au
- 13 Word count: 2998 words

14 **Funding and sponsors**

- 15 The MiND Study is generously funded from the following bodies:
- 16 2020-2024 NHMRC Ideas Grant GNT1185180: The Markers in Neuropsychiatric Disorders
- 17 study.
- 18 MRFF
- 19 Ramsay Health Research Foundation Translation Challenge (2023-2024)

- 20 Matthew Kang is supported by the Research Training Program Scholarship (stipend) from the
- 21 Department of Psychiatry, University of Melbourne with contributions from the Australian
- 22 Commonwealth Government and the Ramsay Health Research Foundation Translation
- 23 Challenge.
- 24 The funders had no role in the design or conduct of this study.

25 Conflicts of interest: None from MK. PBM has received remuneration from Janssen (Australia)

26 for advisory board membership and lectures in the last 3 years.

27

28 Acknowledgements

29 We would like to thank Dr Mu-Hong Chen, Dr Leila Simani, and Dr Wen-Yin Chen for their

30 assistance in providing their published data separately to be included in the meta-analysis. We

31 are also grateful for the correspondence from the following researchers who assisted us in

32 clarifying questions about their published data: Dr Anja Fernqvist, Dr Sterre de Boer, Dr

33 Naghmeh Nikkheslat, Prof Carmine Pariante, Dr. Pedro J. Serrano Castro, Dr Johanna

34 Wallensten, Dr. Carol Van Hulle, Dr Mark Miller, Dr Daniel Alcolea, Dr. Suzanne Schindler,

35 and Dr. Andrew Aschenbrenner.

36 Abstract

Background: Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are biomarkers of neuronal injury measurable in cerebrospinal fluid (CSF) and blood. Despite their potential as diagnostic tests for neurodegenerative disorders, it is unclear how they behave in mood and anxiety disorders. We conducted a systematic review and meta-analysis to investigate whether NfL and GFAP concentrations were altered in adults with mood and anxiety disorders compared to healthy controls.

43

Methods: The study was prospectively registered on PROSPERO (CRD42023434617). We
followed the PRISMA guidelines, searched PubMed, Web of Science, PsycINFO, MEDLINE
and Embase up to the 31/05/2023, and assessed relevant studies and their risk of bias. The
primary outcome was the standardised mean difference (SMD) and 95% confidence interval
(95% CI) of NfL and GFAP concentrations, which was pooled using a random-effects model
adopting the restricted maximum likelihood estimator.

50

51 **Results:** Twenty-one studies met inclusion criteria, comprising of 2327 individuals (695 major 52 depression, 502 bipolar disorder, and 1130 controls). When we compared people with major 53 depression and controls, there was no difference in NfL (SMD = 0.29; 95% CI: -0.10, 0.68) nor 54 GFAP (SMD = 0.47; 95% CI: -0.74, 1.68). In people with bipolar disorder, NfL was 55 significantly elevated compared to controls (SMD = 0.58; 95% CI: 0.16, 0.99). However, the 56 subgroup analysis including more sensitive assay kits (blood Simoa and CSF ELISA), found no 57 significant difference (SMD = 0.40; 95% CI: -0.04, 0.85). Only one study studied GFAP in 58 bipolar disorder. No studies explored NfL nor GFAP concentrations in anxiety disorders. 59 60 **Discussion:** We found that NfL and GFAP concentrations were not elevated in depression. In

bipolar disorder, NfL concentration was elevated, though not in the sensitivity analysis. Our
study informs clinicians about how to interpret these emerging biomarkers in determining

63 whether a person's symptoms are caused by a neurodegenerative or mood disorder.

65 Introduction

Recent developments in blood and cerebrospinal fluid (CSF) biomarkers in neurological 66 67 conditions have offered exciting prospects for enhancing diagnostic assessments. Neurofilament 68 light chain (NfL), a cytoskeletal protein of neurons, has emerged as a sensitive biomarker for 69 assessing neuronal injury (1). Neurodegenerative processes lead to the release of NfL into the 70 CSF, which subsequently pass through to the bloodstream at lower concentrations (2). Although 71 initial studies were limited to measuring NfL in CSF, technological advances have facilitated 72 precise quantification of NfL in blood (3). In particular, blood NfL measured using single-73 molecule array digital immunoassay (Simoa) correlate well with CSF NfL (4). Numerous studies 74 have shown that NfL, in both CSF and blood, is a valuable marker for diagnosing, assessing 75 disease severity, and predicting prognosis in a diverse range of neurodegenerative conditions, 76 including Alzheimer's disease and frontotemporal lobar degeneration (5–7). NfL can also 77 distinguish neurodegenerative disorders from primary psychiatric disorders within memory 78 clinics and neuropsychiatry services (8–10). More recently, glial fibrillary acidic protein 79 (GFAP), a component of glial cell cytoskeleton, has emerged as a sensitive measure of 80 astrogliosis and neuroinflammation, demonstrating superior prognostic accuracy to NfL in 81 multiple sclerosis (11,12).

82

83 Given the potential clinical utility of these biomarkers in determining whether an individual's 84 undifferentiated presentation with psychiatric, cognitive and/or neurological symptoms is due to 85 a neurological or a psychiatric cause, it is crucial to understand how NfL or GFAP behave in 86 primary mood or anxiety disorders. If NfL and GFAP levels remain within normal ranges in 87 primary mood and anxiety disorders, which are the two most prevalent mental disorders (13), 88 such findings would support the use of these biomarkers in distinguishing neurodegenerative 89 conditions at diagnostic assessments. Conversely, should they be elevated in primary mood and 90 anxiety disorders, this may provide insights into their neurobiological underpinnings.

91

92 One of the earliest investigations into NfL and GFAP in psychiatric disorders involved a cohort

93 of elderly women who remained dementia-free during a 10-year follow-up period (14). Those

94 with major depression exhibited significantly higher concentrations of baseline CSF NfL

compared to the rest of the group (major depression mean: 427 ± 186 vs control mean: 277 ± 186

96 ng/L), whilst there was no difference in the GFAP concentrations (major depression mean: 946 \pm

97 196 vs control: 887 ± 308 ng/L). Subsequent studies comparing blood NfL and GFAP in mood

98 disorders to healthy controls have yielded mixed findings, either finding elevated concentrations

- 99 in mood disorders (15–17), or no difference (6,18).
- 100

101 More recent studies have examined the relationship between NfL or GFAP with clinical

102 outcomes in mood disorders. The concentration of GFAP was higher in people with major

103 depression and correlated with the severity of depressive symptoms (17). NfL was found to be

104 negatively correlated with cognitive processing speed in people with major depression compared

to healthy controls (19). Several theories have been proposed to explain why NfL or GFAP may

106 be elevated in mood disorders, including astroglia dysfunction (17), vascular pathology (14), and

- 107 neuroinflammatory processes (20).
- 108

109 Given these conflicting findings in this area of major clinical and scientific importance, we have

110 undertaken a systematic review and meta-analysis of studies investigating NfL and GFAP

111 concentrations in people with mood (depression and bipolar disorder) and anxiety disorders

112 compared to healthy controls. Secondly, we sought to identify any associations between the

severity of mood and anxiety disorders with NfL and GFAP.

114

115 Methods

116 This systematic review was developed using the Preferred Reporting Items for Systematic

117 Reviews and Meta-Analysis (PRISMA) guidelines (21). The protocol was prospectively

registered with PROSPERO (CRD42023434617).

119

120 Eligibility criteria

121 All eligible studies met the following criteria: (1) adult patients diagnosed with either mood

122 (depression and bipolar disorder) or anxiety disorder according to DSM or ICD (22–25); and (2)

123 measured NfL or GFAP in plasma, serum or CSF measured by Simoa,

124 electrochemiluminescence method (ECL) or enzyme linked immunosorbent assay (ELISA).

125 Case-series, meeting abstracts, reviews and meta-analyses were excluded. For articles with

126 overlapped samples, only the report with largest sample size was included.

127	
128	Exclusions criteria were: (1) mood or anxiety disorders due to general medical conditions
129	including dementia and stroke, and (2) co-morbid neurological disorders including multiple
130	sclerosis and dementia.
131	
132	Search strategy
133	Electronic searches were conducted <i>via</i> the Web of Science, PubMed, MEDLINE(OVID),
134	Embase and PsycINFO from the inception of the databases through to 31st May 2023. The
135	search terms included ("neurofilament light" OR "NfL") AND ("glial fibrillary acidic protein"
136	OR "GFAP") AND ("depressi*" OR "bipolar*" OR "anxiet*" OR "mood disorder*"). Studies
137	were required to be in English. We have described our full search strategy in the supplementary
138	file.
139	
140	Study Selection and Data Collection
141	We used Cochrane's Covidence, a web-based systematic review manager, for study selection and
142	quality analysis. One investigator (MK) screened the title and abstracts. Two investigators (MK
143	and JG) independently reviewed the main reports and supplementary materials for their
144	eligibility. We resolved discrepancies by consensus and involved a third senior investigator
145	(MH) when required.
146	
147	The primary outcome was the mean difference of NfL and GFAP in people with mood and
148	anxiety disorders. The mean and standard deviation (SD) of NfL and GFAP was collected in the
149	different cohorts. If this was not available, authors were contacted for the data. If the authors did
150	not respond, the following methods were used to convert the data according to Cochrane
151	Handbook guidelines (26): 1) median, interquartile ranges and minimum/maximum values were
152	converted using an estimation formula (27,28), 2) mean and SD of subgroups (i.e. male and
153	female) were combined using Cochrane's formula (29), and 3) studies that only presented the
154	results in plots were estimated using WebPlotDigitzer (30).
155	
156	Our secondary outcomes were as follows: 1) mood state and severity (measured by a
157	standardised rating scale), 2) duration of mood/anxiety disorder, and 3) cognitive impairment

(measured by a standardised rating scale). We also collected known covariates of NfL and GFAPif they were reported, including age and weight (31).

160

161 Quality of individual studies

Two investigators (MK and JG) independently assessed the quality of included studies using the Newcastle-Ottawa Scale (NOS) quality assessment tool (32). NOS contains a total of 8 small items, and evaluates three aspects: selection, comparability and outcome. Studies were classified as "poor quality" (0-2 points), "average quality" (3-5 points), and "good or high quality" (6-9 points).

167

168 Statistical analysis

169 All statistical analyses were performed using R version 4.2.2 (2022-10-31) and the meta package 170 (33). Meta-analyses were separately conducted for individual psychiatric diagnoses (i.e. major 171 depression and bipolar disorder). For each diagnosis, we calculated standardised mean 172 differences (SMDs) of each biomarker (NfL and GFAP) between psychiatric disorders and 173 controls to be able to pool the different types of assay kits. Of note, Random effects meta-174 analysis models, rather than fixed effects models, were selected a priori based on the theoretical 175 absence of a consistent 'true effect' across the studies. The restricted maximum likelihood 176 estimator was adopted. Ninety-five percent confidence intervals (95% CI) and prediction 177 intervals (PI) were calculated and visualised using forest plots. A PI quantifies the likely range in 178 which a new study's effect size will fall into, assuming that this future study is of a similar nature 179 to those meta-analysed. We assumed a two-sided P < 0.05 to indicate statistical significance. 180

Where there were a sufficient number of studies, sensitivity analyses were performed to ensure any findings were consistent with the main analyses: type of biomarker analysis (i.e. CSF ELISA and serum/plasma Simoa; blood Simoa) and studies that used age-matched controls. We intended to analyse further subgroups including duration of psychiatric illness and age at diagnosis, however there was an insufficient number of studies.

186

We performed meta regression on the severity of mood symptoms as measured by the scalesused in the study (i.e. Hamilton's Depression Rating Scale; HDRS and Montgomery-Asberg

189	Depression Rating	Scale; MADRS)). We could not	perform other meta	regression analyses
		, , ,			

- 190 including variables such as cognition, duration of psychiatric illness and number of mood
- 191 disorder episodes due to the limited numbers of studies.
- 192
- 193 As a post-hoc analysis to include studies (all of which used Simoa assay kits) that did not have
- any control groups, we used a robust mixed-means model to compare the mean concentration of
- 195 NfL and GFAP between cases (depression or bipolar) and controls.
- 196
- 197 We assessed for publication bias using funnel plots of the effect sizes of mood disorders for NfL
- and GFAP. We performed meta-analyses only where there were at least five studies to ensure
- 199 acceptable statistical power to make an inference. I^2 and tau² statistics were used to quantify
- 200 between-study heterogeneity in the meta-analyses.
- 201

202 **Results**

- 203 Study selection
- 204 The systematic search identified 2,890 unique studies, of which 110 were selected for full-text
- 205 review. Twenty-one studies met our inclusion criteria for the meta-analysis, as shown in Figure
- 206 1. Twelve studies investigated major depression, five bipolar disorder, four reported data on
- both, and no studies reported on other types of mood disorders nor anxiety disorders.
- 208
- 209 The main reason that some full-text articles were excluded was due to studies either not reporting
- 210 or collecting individual psychiatric diagnoses. A number of studies used a less rigorous process
- to collect diagnoses (self-report, file review and diagnosis based on a cut-off score from a mood
- rating scale) (34). Four studies had an insufficient sample size (n<10) (9,35,36). Some studies
- 213 used indirect measures of NfL and GFAP, including extracellular vesicles, mRNA, IgG
- autoantibodies and urine (37–40).
- 215

216 Study characteristics

Final sample data were obtained for 2327 individuals, of which 695 had major depression, 502

- 218 bipolar disorder, and 1130 healthy controls. Two studies (41,42) did not have a healthy control
- group, so were only included in the additional mixed-model meta-analyses. Seventeen studies

analysed blood samples, three used CSF, and Knorr et al's study (16) investigated both CSF and

blood. The majority of the studies (75%) were published after 2020, reflecting the relatively

recent availability of Simoa and ELISA technology to measure NfL and GFAP in blood. (Tables

- 223 1-2)
- 224

Although Ashton et al. (2021) reported that the sample size of their control (cognitively

unimpaired and CSF amyloid- β negative) and depression groups were 130 and 37 respectively,

this conflicted with their supplementary data source table that reported 115 and 51 values

respectively. We chose to perform the meta-analysis with the latter values, as they matched the

sex proportions reported in their main table. Bavato et al. (2021) drew on 295 healthy controls

and referenced their earlier work (Barro et al., 2018, n=258) for the characteristics of the healthy

- controls, which is included in this meta-analysis instead.
- 232

233 **Quality of studies**

The quality of studies was considered at least moderate across studies. The area of low quality

was in the domain of comparability due to the inequalities in age and sex between study groups,

- as summarised in the supplementary eTable 1.
- 237

238 Synthesis of results

239 Major depression

240 Neurofilament light chain

241 *All studies (Figure 2a):* There was no significant difference in the concentration of NfL in

people with major depression compared to healthy controls (SMD = 0.29; 95% CI: -0.10, 0.68).

243 The prediction interval for this pooled mean difference was very wide (PI: -1.11, 1.69) with

significant heterogeneity ($I^2 = 90\%$; tau² = 0.37). A regression-based Egger's test did not show

any evidence of small study effects (p-value = 0.35) though on visual inspection of the funnel

- 246 plot (supplementary eFigure 1), Ashton et al's study's was an outlier (6). This study had a
- significant age difference between the depression and control groups (mean difference 31.7
- 248 years).

249 In the subgroup analysis of studies that included age-matched controls (Figure 2b), NfL was

significantly higher in major depression, though with a wide PI (SMD = 0.44; 95% CI: 0.11,

251 0.77; PI: -0.61, 1.50). The subgroup analysis model which only included data using CSF

- 252 *ELISA and blood Simoa (Figure 2c)*, which are more accurate measures of NfL (2,4), found no
- significant difference (SMD = -0.03, 95% CI: -0.53, 0.47). The heterogeneity for both subgroup
- analysis models were high ($I^2 = 79\%$, tau² = 0.17 and $I^2 = 57\%$, tau² = 0.07 respectively).
- 255 Similarly, the subgroup analysis model including six age-matched studies that used CSF ELISA
- and Simoa also found no significant difference (SMD = 0.1195% CI: -0.32, 0.55).
- 257
- 258 A random-effects meta-regression model which included all NfL studies suggested that mood
- severity did not influence NfL. In the subgroup mixed-model mean analysis of studies that only
- 260 used blood Simoa, we found no significant difference in NfL levels.
- 261

262 Glial fibrillary acidic protein

- 263 GFAP (Figure 2d) was not significantly different between people with major depression and
- 264 healthy controls (SMD = 0.47; 95% CI: -0.74, 1.68; PI: -3.09, 4.03), with significant
- heterogeneity between the studies ($I^2 = 92\%$, tau² = 0.53). There was insufficient data to perform
- additional meta-regressions including cognition and GFAP.
- 267

268 Bipolar disorder

269 Neurofilament light chain

- 270 *All studies (Figure 3a):* The mean concentration of NfL in people with bipolar disorder was
- significantly higher than healthy control (SMD = 0.58; 95% CI: 0.16, 0.99). However, the
- 272 prediction interval for this pooled mean difference was wide (PI: -0.67, 1.82) with significant
- heterogeneity ($I^2 = 84.0\%$, tau² = 0.24). As Knorr et al's study (2022) reported both CSF ELISA
- and plasma Simoa samples, we performed a sensitivity analysis where we excluded the Simoa
- 275 dataset, which found NfL was still significantly higher in bipolar disorder compared to healthy
- controls (SMD = 0.62; 95% CI: 0.14, 1.09), There was no asymmetry on the funnel plot
- (supplementary eFigure 1), and we could not use Egger's test due to insufficient number ofstudies.
- 279 The subgroup analysis model with age-matched studies (Figure 3b) demonstrated significantly
- 280 higher NfL in bipolar disorder (SMD = 0.50; 95% CI: 0.06, 0.94; PI: -0.74, 1.74). For the
- subgroup analysis including only CSF ELISA and blood Simoa studies (Figure 3c), there was

282 no significant difference in the mean concentration of NfL between bipolar disorder and healthy

- 283 controls (SMD = 0.40; 95% CI: -0.04, 0.85) with a wide prediction interval (PI: -0.80, 1.61).
- Both models were heterogenous ($I^2 = 82.0\%$, tau² = 0.22 and $I^2 = 81.8\%$, tau² = 0.18
- respectively). The subgroup analysis including six age-matched studies which used CSF ELISA
- and Simoa also found no significant difference in mean NfL between bipolar disorder and
- healthy controls. (SMD = 0.27 95% CI: -0.12, 0.65). We performed a subgroup mixed-model
- 288 mean analysis of blood Simoa studies which showed no difference in NfL concentrations.
- 289

290 Glial fibrillary acidic protein

- 291 Only one study (17) studied GFAP in people with bipolar disorder (n=11), which found GFAP
- 292 concentrations were similar in bipolar disorder compared to healthy controls (125 ± 50 vs $147 \pm$
- 293 61 pg/mL).
- 294

295 **Discussion**

296 Our systematic review found that NfL and GFAP concentrations were not elevated in people

297 with major depression compared to healthy controls. NfL was elevated in people with bipolar

298 disorder, though the difference was no longer significant with subgroup analysis using more

sensitive assay kits (CSF ELISA and blood Simoa). We identified no studies examining NfL or

300 GFAP in people with anxiety disorders. To the best of our knowledge, this is the most

301 comprehensive systematic review of these biomarkers in people with primary mood and anxiety302 disorders.

303

304 Our findings align with the existing literature supporting the use of these biomarkers in the 305 differentiation between mood disorders and neurodegenerative disorders (2,5,6). The complex 306 relationship between mood disorders and neurodegenerative disorders, which can present with 307 overlapping symptoms or co-occur, necessitates careful assessment. These findings provide 308 reassurance to clinicians that people with primary mood disorders are unlikely to have very 309 elevated concentrations of NfL and GFAP, as seen in the majority of neurodegenerative 310 disorders where there often is marked elevation (for example, 1.86-fold in Alzheimer's disease, 311 3.91-fold in frontotemporal dementia; 44,45).

313 In individuals with mood disorders, we noted variable instances where NfL concentration was 314 elevated compared to healthy controls, indicating that neuronal injury or neuroinflammation 315 might be present in a specific subset. The limitations of the available data, including detailed 316 clinical and treatment information, prevented us from being able to investigate this further. We 317 plan to conduct a 'mega-analysis' by pooling the raw data from the studies included. This approach will enable us to perform statistical adjustments for known covariates including as age, 318 319 sex and weight/BMI, which were not possible in the meta-analysis. Moreover, identifying 320 specific clusters of symptomatology that correlate with NfL/GFAP may offer valuable insights 321 into the neurodegenerative and neuroinflammatory phenotypes within mood disorders. In turn, 322 opens a new paradigm of diagnosis and treatment for these patients based on biomarker data as 323 well as reported symptoms, in line with the RDOC Framework (56).

324

Despite the widespread prevalence and burden of anxiety disorders (13), no prior research has
explored NfL and GFAP in individuals with primary anxiety disorders. This is an important gap
in the literature that this systematic review has identified for the use of NfL and GFAP in clinical
practice.

329

330 The review process faced several limitations. The evidence was constrained by the quality and 331 heterogeneity of included studies. Controls were not consistently age- and sex-matched (6,18), 332 and some studies lacked control subjects (41,42,51). The limited number of studies and data 333 precluded adequate adjustment for known covariates of NfL and GFAP, such as age, sex, 334 weight/BMI, and renal function (2). This also hindered exploration of factors like mood disorder 335 states (euthymic vs depressed) or effects of psychotropic medications (46). Furthermore, to 336 harmonise the dataset, some of the meta-analyses relied on estimates derived from raw data, 337 which may have introduced potential inaccuracies in the true estimates. Despite our attempts to 338 include as many articles as possible by searching important databases, grey literature, as well as 339 snowballing for other relevant articles, it is possible that some studies may have been 340 inadvertently omitted.

341

342

343 Conclusions

011	
345	Our primary analysis indicated that NfL and GFAP levels were not significantly elevated in
346	major depression, while in bipolar disorder, NfL was elevated compared to controls. Subgroup
347	analysis using more sensitive assays revealed no notable differences. These findings suggest that
348	NfL and GFAP elevations in mood disorders are minimal, contrasting with the large elevations
349	in neurodegenerative disorders. This supports the use of these biomarkers in clinical settings to
350	distinguish psychiatric from neurodegenerative causes. The practicality of blood-based
351	biomarker measurements offers valuable diagnostic insights to answer the common clinical
352	question faced by patients, carers and clinicians.
353	

354 **References**

- Gaetani L, Blennow K, Calabresi P, Filippo MD, Parnetti L, Zetterberg H. Neurofilament
 light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019
 Aug 1;90(8):870–81.
- Arslan B, Zetterberg H. Neurofilament light chain as neuronal injury marker what is
 needed to facilitate implementation in clinical laboratory practice? Clinical Chemistry and
 Laboratory Medicine (CCLM). 2023 Jun 27;61(7):1140–9.
- Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments
 as biomarkers in neurological disorders. Nature Reviews Neurology. 2018 Oct;14(10):577–
 89.
- Alagaratnam J, von Widekind S, De Francesco D, Underwood J, Edison P, Winston A, et al.
 Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis. BMJ Neurol Open. 2021 Jun 16;3(1):e000143.
- 367 5. Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli Ö, Maceski A, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. The Lancet Neurology. 2022 Mar;21(3):246–57.
- Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, et al. A
 multicentre validation study of the diagnostic value of plasma neurofilament light. Nat
 Commun. 2021 Jun 7;12(1):3400.
- Eratne D, Loi SM, Li QX, Stehmann C, Malpas CB, Santillo A, et al. Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings.
 Alzheimer's & Dementia. 2022;18(11):2218–33.
- Eratne D, Kang M, Malpas C, Simpson-Yap S, Lewis C, Dang C, et al. Plasma
 neurofilament light in behavioural variant frontotemporal dementia compared to mood and
 psychotic disorders. Aust N Z J Psychiatry. 2023 Jul 21;00048674231187312.
- 381
 9. Kang MJ, Eratne D, Dobson H, Malpas CB, Keem M, Lewis C, et al. Cerebrospinal fluid
 aneurofilament light predicts longitudinal diagnostic change in patients with psychiatric and
 aneurodegenerative disorders. Acta Neuropsychiatrica. 2023 Apr 28;1–36.
- Willemse EAJ, Scheltens P, Teunissen CE, Vijverberg EGB. A neurologist's perspective on
 serum neurofilament light in the memory clinic: a prospective implementation study. Alz
 Res Therapy. 2021 Dec;13(1):101.
- 11. Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D'Anna L, Huss A, et al. Blood GFAP as
 an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022
 Mar;18(3):158–72.

- Meier S, Willemse EAJ, Schaedelin S, Oechtering J, Lorscheider J, Melie-Garcia L, et al.
 Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a
 Biomarker for Disease Progression in Multiple Sclerosis. JAMA Neurology. 2023 Mar
 1;80(3):287–97.
- 394 13. GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12
 395 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the
 396 Global Burden of Disease Study 2019. The Lancet Psychiatry. 2022 Feb 1;9(2):137–50.
- 397 14. Gudmundsson P, Skoog I, Waern M, Blennow K, Zetterberg H, Rosengren L, et al. Is there a
 398 CSF biomarker profile related to depression in elderly women? Psychiatry Research.
 399 2010;176(2–3):174–8.
- 400 15. Hviid CVB, Benros ME, Krogh J, Nordentoft M, Christensen SH. Serum glial fibrillary
 401 acidic protein and neurofilament light chain in treatment-naïve patients with unipolar
 402 depression. Journal of Affective Disorders. 2023 Oct 1;338:341–8.
- 403 16. Knorr U, Simonsen AH, Jensen CS, Zetterberg H, Blennow K, Akhøj M, et al. Alzheimer's
 404 disease related biomarkers in bipolar disorder A longitudinal one-year case-control study. J
 405 Affect Disord. 2022 Jan 15;297:623–33.
- 406 17. Steinacker P, Al Shweiki MR, Oeckl P, Graf H, Ludolph AC, Schönfeldt-Lecuona C, et al.
 407 Glial fibrillary acidic protein as blood biomarker for differential diagnosis and severity of
 408 major depressive disorder. Journal of Psychiatric Research. 2021 Dec;144:54–8.
- 409 18. Huang MC, Chen CH, Liu TH, Chung AN, Liu YL, Quednow BB, et al. Comorbidity of
 410 ketamine dependence with major depressive disorder increases the vulnerability to
 411 neuroaxonal pathology. Journal of Psychiatric Research. 2023 Feb;158:360–4.
- 412 19. Bavato F, Cathomas F, Klaus F, Gütter K, Barro C, Maceski A, et al. Altered neuroaxonal
 413 integrity in schizophrenia and major depressive disorder assessed with neurofilament light
 414 chain in serum. Journal of Psychiatric Research. 2021 Aug;140:141–8.
- 20. Michel M, Fiebich BL, Kuzior H, Meixensberger S, Berger B, Maier S, et al. Increased
 GFAP concentrations in the cerebrospinal fluid of patients with unipolar depression. Transl
 Psychiatry. 2021 Jun;11(1):308.
- 418 21. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
 419 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021
 420 Mar 29;n71.
- 421 22. American Psychiatric Association, American Psychiatric Association. Diagnostic and
 422 statistical manual of mental disorders: DSM-IV-TR. 4th ed., text revision. Washington, DC:
 423 American Psychiatric Association; 2000. 943 p.
- 424 23. American Psychiatric Association, American Psychiatric Association, editors. Diagnostic
 425 and statistical manual of mental disorders: DSM-5. 5th ed. Washington, D.C: American
 426 Psychiatric Association; 2013. 947 p.

427 24. Sheehan DV. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The 428 Development and Validation of a Structured Diagnostic Psychiatric Interview for DSM-IV 429 and ICD-10. J Clin Psychiatry. 1998; 430 25. World Health Organization. International statistical classification of diseases and related 431 health problems (11th ed.) [Internet]. 2019. Available from: https://icd.who.int/ 432 26. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane 433 Handbook for Systematic Reviews of Interventions [Internet]. 1st ed. Wiley; 2019 [cited 434 2024 Jan 12]. Available from: 435 https://onlinelibrary.wiley.com/doi/book/10.1002/9781119536604 436 27. Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, 437 median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018 Jun;27(6):1785-438 805. 439 28. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from 440 the sample size, median, range and/or interquartile range. BMC Medical Research 441 Methodology. 2014 Dec 19;14(1):135. 442 29. Higgins J, Li T, Deeks J. Chapter 6: Choosing effect measures and computing estimates of 443 effect [Internet]. Vol. Cochrane Handbook for Systematic Reviews of Interventions version 444 6.0. Cochrane; 2019 [cited 2023 Dec 24]. Available from: 445 https://training.cochrane.org/handbook/current/chapter-06 446 30. Rohatgi A. WebPlotDigitizer [Internet]. Pacifica, California, USA; 2022 [cited 2023 Oct 31]. 447 Available from: https://automeris.io/WebPlotDigitizer 448 31. Simrén J, Andreasson U, Gobom J, Suarez Calvet M, Borroni B, Gillberg C, et al. 449 Establishment of reference values for plasma neurofilament light based on healthy 450 individuals aged 5–90 years. Brain Communications. 2022 Jul 4:4(4):fcac174. 451 32. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle -Ottawa 452 scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses [Internet]. 453 2011 [cited 2024 Jan 12]. Available from: 454 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp 455 33. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical 456 tutorial. Evid Based Mental Health. 2019 Nov;22(4):153-60. 457 34. Serrano-Castro PJ, Garzón-Maldonado FJ, Casado-Naranjo I, Ollero-Ortiz A, Mínguez-458 Castellanos A, Iglesias-Espinosa M, et al. The cognitive and psychiatric subacute impairment 459 in severe Covid-19. Sci Rep. 2022 Mar 3;12(1):3563. 460 35. Fernqvist A, Alexiou E, Zetterberg H, Howner K, Nilsson T, Andiné P. Plasma 461 neurofilament light chain protein is not increased in forensic psychiatric populations: a pilot 462 study. Front Psychiatry. 2023 May 4;14:1176266.

- 36. Zachrisson OCG, Balldin J, Ekman R, Naesh O, Rosengren L, Ågren H, et al. No evident
 neuronal damage after electroconvulsive therapy. Psychiatry Research. 2000 Oct;96(2):157–
 65.
- 466 37. Ferensztajn-Rochowiak E, Tarnowski M, Samochowiec J, Michalak M, Ratajczak MZ,
 467 Rybakowski JK. Increased mRNA expression of peripheral glial cell markers in bipolar
 468 disorder: The effect of long-term lithium treatment. European Neuropsychopharmacology.
 469 2016 Sep;26(9):1516–21.
- 38. Poletaev AB, Morozov SG, Gnedenko BB, Zlunikin VM, Korzhenevskey DA. Serum AntiSlOOb, Anti-GFAP and Anti-NGF Autoantibodies of IgG Class in Healthy Persons and
 Patients with Mental and Neurological Disorders. Autoimmunity. 2000 Jan;32(1):33–8.
- 473 39. van Engelen MPE, Heijst H, Willemse EAJ, Oudega ML, Vermunt L, Scheltens P, et al.
 474 Urine as matrix for analysis of neurofilament light chain is not suitable to distinguish
 475 frontotemporal dementia from psychiatric diseases. Brain Communications. 2023;5(2).
- 476 40. Wallensten J, Mobarrez F, Åsberg M, Borg K, Beser A, Wilczek A, et al. Isoforms of soluble
 477 vascular endothelial growth factor in stress-related mental disorders: a cross-sectional study.
 478 Sci Rep. 2021 Aug 17;11(1):16693.
- 479 41. Katisko K, Cajanus A, Jääskeläinen O, Kontkanen A, Hartikainen P, Korhonen VE, et al.
 480 Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar 481 degeneration and primary psychiatric disorders. J Neurol. 2020 Jan;267(1):162–7.
- 482
 42. Katisko K, Cajanus A, Huber N, Jääskeläinen O, Kokkola T, Kärkkäinen V, et al. GFAP as a
 483
 484
 484
 484
 485
 486
 486
 486
 487
 487
 486
 486
 486
 487
 487
 486
 486
 486
 486
 487
 486
 486
 486
 487
 487
 487
 488
 488
 488
 489
 489
 480
 480
 480
 480
 481
 481
 481
 482
 482
 483
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 <l
- 43. Bai YM, Liu YL, Kuo HW, Tsai SJ, Hsu JW, Huang KL, et al. Procollagen type 1 Nterminal propeptide, neurofilament light chain, proinflammatory cytokines, and cognitive
 function in bipolar and major depressive disorders: An exploratory study of brain– bone axis
 and systemic inflammation. Journal of Psychiatric Research. 2023 Feb;158:403–8.
- 489 44. Besse M, Belz M, Folsche T, Vogelgsang J, Methfessel I, Steinacker P, et al. Serum
 490 neurofilament light chain (NFL) remains unchanged during electroconvulsive therapy. The
 491 World Journal of Biological Psychiatry. 2020 Feb 7;21(2):148–54.
- 492
 45. Chen MH, Liu YL, Kuo HW, Tsai SJ, Hsu JW, Huang KL, et al. Neurofilament light chain is
 a novel biomarker for major depression and related executive dysfunction. International
 Journal of Neuropsychopharmacology. 2022;25(2):99–105.
- 46. Jiang L, Shen Z, Cheng Y, Lu J, He B, Xu J, et al. Elevated serum neurofilament levels in
 young first-episode and medication-naïve major depressive disorder patients with alterative
 white matter integrity. Psychiatry Research: Neuroimaging. 2021 Nov;317:111351.

- 47. Ramezani M, Simani L, Fard MG, Abbaszadeh F, Shadnia S. Increased levels of
 neurofilament light chain in suicide attempters' serum. Translational Neuroscience. 2022
 Aug 5;13(1):218–23.
- 48. Wallensten J, Mobarrez F, Åsberg M, Borg K, Beser A, Wilczek A, et al. Plasma levels of
 S100B and neurofilament light chain protein in stress-related mental disorders. Sci Rep.
 2022 May 18;12(1):8339.
- 49. Aggio V, Fabbella L, Finardi A, Mazza EB, Colombo C, Falini A, et al. Neurofilaments
 light: Possible biomarker of brain modifications in bipolar disorder. Journal of Affective
 Disorders. 2022 Mar;300:243–8.
- 507 50. Al Shweiki MR, Steinacker P, Oeckl P, Hengerer B, Danek A, Fassbender K, et al.
 508 Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from
 509 behavioural variant frontotemporal dementia. Journal of Psychiatric Research.
 510 2019;113(February):137–40.
- 511 51. Chen WY, Huang MC, Chiu CC, Cheng YC, Kuo CJ, Chen PY, et al. The interactions
 512 between vitamin D and neurofilament light chain levels on cognitive domains in bipolar
 513 disorder. BJPsych open. 2022 Nov;8(6):e207.
- 514 52. Rolstad S, Jakobsson J, Sellgren C, Ekman CJ, Blennow K, Zetterberg H, et al. Cognitive
 performance and cerebrospinal fluid biomarkers of neurodegeneration: a study of patients
 with bipolar disorder and healthy controls. PloS one. 2015;10(5):e0127100–e0127100.
- 517 53. Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y, et al. Serum
 518 neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in
 519 multiple sclerosis. Brain. 2018 Aug 1;141(8):2382–91.
- 520 54. Bridel C, Van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, Alvarez-Cermeño
 521 JC, et al. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in
 522 Neurology: A Systematic Review and Meta-analysis. JAMA Neurology. 2019
 523 Jun;76(9):1035–48.
- 524 55. Eratne D, Keem M, Lewis C, Kang M, Walterfang M, Farrand S, et al. Cerebrospinal fluid
 525 neurofilament light chain differentiates behavioural variant frontotemporal dementia
 526 progressors from non-progressors. Journal of the Neurological Sciences. 2022
 527 Nov;442:120439.
- 528 56. Cuthbert BN. Research Domain Criteria (RDoC): Progress and Potential. Curr Dir Psychol
 529 Sci. 2022 Apr 1;31(2):107–14.
- 530
- 531

532 Figures



534 Figure 1. PRISMA Diagram for study selection

	/lajor de	pression	Standardised	Mean						
Study	Total	Mean	SD	Total	Mean	SD	Difference	e SMD	95%-C	Weight
	BI	ood Sin	noa							
Ashton et al. 2021	51	11.19	5.8000	114	22.52	10.6600		-1.19	[-1.55; -0.84	8.2%
Huang et al. 2023	35	5.40	2.2000	86	6.70	2.7000		-0.50	[-0.90; -0.10]	8.0%
Hviid et al. 2023	110	7.68	3.0137	33	7.60	3.1373		0.03	[-0.36; 0.42	8.1%
Eratne et al. 2023	42	10.88	7.0100	96	9.36	14.1500		- 0.12	[-0.24; 0.48	8.2%
Besse et al. 2020	15	17.41	11.8800	15	15.57	9.5995		0.17	[-0.55; 0.88	6.5%
Bavato et al. 2021	41	26.31	10.4000	258	24.48	9.6170		- 0.19	[-0.14; 0.52	8.3%
Steinacker et al. 2021	45	29.30	35.3000	16	15.20	7.1000		• 0.45	[-0.12; 1.03	7.2%
Random effects model	339			618				-0.13	[-0.65; 0.40]	54.5%
Heterogeneity: $I^2 = 87\%$, τ^2	= 0.2792	2, <i>p</i> < 0.0	1							
	BI	ood ELI	SA							
Wallensten et al. 2022	31	357.40	87.1000	61	306.40	115.7000		• 0.47	[0.03; 0.91]	7.9%
Bai et al. 2023	24	22.43	12.2761	29	16.74	6.8072		• 0.58	[0.03; 1.13	7.3%
Chen et al. 2021	40	28.76	22.5300	40	16.65	8.0700		• 0.71	[0.26; 1.16	7.8%
Jiang et al. 2021	82	439.42	259.5908	72	187.91	201.0015		———	[0.73; 1.41	8.2%
Ramezani et al. 2022	28	41.35	35.1865	35	13.72	5.1094		···· 1.15	[0.61; 1.69]	7.4%
Random effects model	205			237				0.81	[0.44; 1.18	38.6%
Heterogeneity: $I^2 = 42\%$, $\tau^2 =$	= 0.0387	7, p = 0.1	4						•	
	CS	SF ELIS	A							
Gudmundsson et al. 2010	11	427.00	318.0000	65	277.00	186.0000		• 0.71	[0.06; 1.36	6.9%
Random effects model Prediction interval	555			920				0.29	[-0.10; 0.68 [-1.11; 1.69	100.0%
Test for subgroup difference	= 0.3708 s: $\chi_2^2 = 1$	s, <i>p</i> < 0.0 3.92, df	= 2 (p < 0.0	01)			-1.5 -1 -0.5 0 0	0.5 1 1.5		

535

536 Figure 2a. Forest plot of NfL in major depression (all studies)

- 537
- 538
- 539

Major depression Control Standardised Mean Study Total Mean SD Total Mean SD Difference SMD 95%-CI Weight Blood ELISA 31 357.40 87.1000 61 306.40 115.7000 [0.03; 0.91] Wallensten et al. 2022 0.47 9.6% Bai et al. 2023 22.43 12.2761 29 16.74 6.8072 0.58 [0.03; 1.13] 8.5% 24 Chen et al. 2021 28.76 22.5300 8.0700 0.71 [0.26; 9.4% 40 40 16.65 1.16] Jiang et al. 2021 82 439.42 259.5908 72 187.91 201.0015 1.07 [0.73; 1.41] 10.4% Ramezani et al. 2022 28 41.35 35.1865 35 13.72 5.1094 1.15 [0.61; 1.69] 8.7% Random effects model 205 237 0.81 [0.44; 1.18] 46.7% Heterogeneity: $I^2 = 42\%$, $\tau^2 = 0.0387$ p = 0.14Blood Simoa 2.2000 -0.50 [-0.90; -0.10] Huang et al. 2023 35 5.40 86 6.70 2.7000 9.9% Hviid et al. 2023 110 7.68 3.0137 33 7.60 3.1373 0.03 [-0.36; 0.42] 10.0% Eratne et al. 2023 42 10.88 7.0100 96 9.36 14.1500 0.12 [-0.24; 0.48] 10.2% Besse et al. 2020 15 17.41 11.8800 15 15.57 9.5995 0.17 [-0.55; 0.88] 7.1% Steinacker et al. 2021 45 29.30 35.3000 16 15.20 7.1000 0.45 [-0.12; 1.03 8.3% 247 246 0.02 [-0.42; 0.45] Random effects model 45.6% Heterogeneity: $I^2 = 56\%$, τ^2 CSF ELISA Gudmundsson et al. 2010 11 427.00 318.0000 65 277.00 186.0000 0.71 [0.06; 1.36] 7.7% Random effects model 463 548 0.44 [0.11; 0.77] 100.0% Prediction interval Heterogeneity: $I^2 = 81\%$, $\tau^2 = 0.1946$, p < 0.01[-0.61; 1.50] Test for subgroup differences: χ^2_2 = 15.21, df = 2 (p < 0.01) -1.5 -1 -0.5 0 0.5 1 1.5

- 541 Figure 2b. Forest plot of NfL in major depression (age-matched studies only)
- 542

Major depression							Standardised Mean			
Study	Total	Mean	SD	Total	Mean	SD	Difference	SMD	95%-CI	Weight
	_						3			
	BI	ood Sin	10a							
Ashton et al. 2021	51	11.19	5.8000	114	22.52	10.6600 -		-1.19	[-1.55; -0.84]	13.5%
Huang et al. 2023	35	5.40	2.2000	86	6.70	2.7000		-0.50	[-0.90; -0.10]	13.2%
Hviid et al. 2023	110	7.68	3.0137	33	7.60	3.1373		0.03	[-0.36; 0.42]	13.2%
Eratne et al. 2023	42	10.88	7.0100	96	9.36	14.1500	— <u> </u>	0.12	[-0.24; 0.48]	13.4%
Besse et al. 2020	15	17.41	11.8800	15	15.57	9.5995		0.17	[-0.55; 0.88]	10.4%
Bavato et al. 2021	41	26.31	10.4000	258	24.48	9.6170	- 	0.19	[-0.14; 0.52]	13.7%
Steinacker et al. 2021	45	29.30	35.3000	16	15.20	7.1000		0.45	[-0.12; 1.03]	11.6%
Random effects model	339			618				-0.13	[-0.65; 0.40]	89.0%
Heterogeneity: $I^2 = 87\%$, $\tau^2 =$	= 0.2792	2, p < 0.0	1							
	CS	SF ELIS	A							
Gudmundsson et al. 2010	11	427.00	318.0000	65	277.00	186.0000		0.71	[0.06: 1.36]	11.0%
									, ,	
Random effects model	350			683				-0.03	[-0.53; 0.47]	100.0%
Prediction interval									I-1.49: 1.421	
Heterogeneity: $I^2 = 87\%$, $\tau^2 =$	= 0.3076	6. p < 0.0	1					Г		
Test for subgroup differences	$s^2 = 4$	151 df =	1(p = 0.03)	3)		-1	5 -1 -05 0 05 1 1	5		
root of subgroup differences	· ~1	, ui –	· (p = 0.00	· /		- 1				

544 Figure 2c. Forest plot of NfL in major depression (Simoa and CSF studies only)

		Major	depressi	on		Control	Standardised Mean			
Study	Total	Mean	SD	Total	Mean	SD	Difference	SMD	95%-CI	Weight
	C	SF ELIS	6A							
Gudmundsson et al. 2010) 11	946.00	196.0000	65	887.00	308.0000	÷	0.20	[-0.44; 0.84]	23.5%
Michel et al. 2021	102	733.22	401.4200	39	245.56	176.2500		1.37	[0.97; 1.77]	26.1%
Random effects model	113			104				- 0.81	[-6.62; 8.24]	49.6%
Heterogeneity: $I^2 = 89\%$, τ^2	= 0.611	2, <i>p</i> < 0.0	01							
	В	lood Sir	noa							
Hviid et al. 2023	110	63.74	23.8216	33	74.16	35.1548		-0.39	[-0.78; 0.01]	26.2%
Steinacker et al. 2021	45	211.00	99.0000	16	147.00	61.0000		0.70	[0.11; 1.28]	24.2%
Katisko et al. 2021	22	224.00	113.0000		12					0.0%
Random effects model	177			49				0.13	[-6.73; 7.00]	50.4%
Heterogeneity: $I^2 = 89\%$, τ^2	= 0.520	7, p < 0.0	01							
Random effects model	290			153				0.47	[-0.74; 1.68]	100.0%
Prediction interval									[-3.09; 4.03]	
Heterogeneity: $I^2 = 92\%$, τ^2	= 0.533	0, p < 0.0	01							
Test for subgroup difference	es: $\chi_1^2 = 0$	0.73, df =	= 1 (p = 0.39)	9)			-5 0 5			

- 549 Figure 2d. Forest plot of GFAP in major depression

Study	Bipolar d Total Mean	lisorder SD Total	Mean	Control SD	Standardised Mean Difference	SMD	95%-CI	Weight
Eratne et al. 2023 Knorr et al. 2022 Steinacker et al. 2021 Al Shweiki et al. 2019 Aggio et al. 2022 Random effects model Heterogeneity: $I^2 = 81\%$, n	Blood Sim 121 8.35 85 6.96 11 21.20 1 11 23.07 1 45 9.13 273 ² = 0.1988, <i>p</i> < 0.0	4.7600 96 3.0920 44 16.6000 16 15.8767 27 4.7800 29 212	9.36 6.04 15.20 17.08 4.28	14.1500 2.5597 7.1000 8.7144 2.3900	 +++ 	-0.10 0.31 0.49 0.52 1.19 0.45	[-0.37; 0.17] [-0.05; 0.68] [-0.29; 1.27] [-0.19; 1.24] [0.69; 1.70] [-0.16; 1.06]	13.1% 12.4% 8.5% 9.2% 11.1% 54.3%
Bai et al. 2023 Ramezani et al. 2022 Random effects model Heterogeneity: $J^2 = 0\%$, τ^2	Blood ELI 25 28.47 1 22 39.45 3 47 = 0, <i>p</i> = 0.86	SA 12.3859 29 32.1045 35 64	16.74 13.72	6.8072 5.1094	**	1.18 1.25 1.22	[0.60; 1.76] [0.67; 1.84] [0.76; 1.68]	10.4% 10.3% 20.7%
Knorr et al. 2022 Rolstad et al. 2015 Random effects model Heterogeneity: / ² = 91%, n	CSF ELIS/ 85 353.49 17 82 485.73 42 167 -2 = 0.3342, <i>p</i> < 0.0	A 75.7168 44 5 25.6200 71 5 115 1	379.52 254.38	269.7610 55.4200		-0.12 0.73 — 0.31	[-0.49; 0.24] [0.40; 1.06] [-5.12; 5.74]	12.4% 12.7% 25.0%
Random effects model Prediction interval Heterogeneity: / ² = 84%, n Test for subgroup differen	487 $x^2 = 0.2424, p < 0.0$ ces: $\chi_2^2 = 16.09, df =$	391 1 = 2 (p < 0.01)			-4 -2 0 2 4	0.58	[0.16; 0.99] [-0.67; 1.82]	100.0%

554

Study	Bipolar disorder Total Mean SD	(Total Mean	Control Standardised Mear SD Difference	n SMD 95%-Cl Weigl
Eratne et al. 2023 Knorr et al. 2022 Steinacker et al. 2021 Al Shweiki et al. 2019 Random effects mode Heterogeneity: $l^2 = 48\%$,	Blood Simoa 121 8.35 4.7600 85 6.96 3.0920 11 21.20 16.6000 11 23.07 15.8767 1 228 $r^2 = 0.0517, p = 0.12$	96 9.36 1 44 6.04 16 15.20 27 17.08 183	4.1500 2.5597 7.1000 8.7144	-0.10 [-0.37; 0.17] 14.9' 0.31 [-0.05; 0.68] 14.0' 0.49 [-0.29; 1.27] 9.4' 0.52 [-0.19; 1.24] 10.1' 0.20 [-0.27; 0.68] 48.5'
Bai et al. 2023 Ramezani et al. 2022 Random effects mode Heterogeneity: $J^2 = 0\%, \tau^2$	Blood ELISA 25 28.47 12.3859 22 39.45 32.1045 1 47 $^2 = 0, p = 0.86$	29 16.74 35 13.72 64	6.8072 5.1094	1.18 [0.60; 1.76] 11.6 1.25 [0.67; 1.84] 11.6 1.22 [0.76; 1.68] 23. 1
Knorr et al. 2022 Rolstad et al. 2015 Random effects mode Heterogeneity: / ² = 91%,	CSF ELISA 85 353.49 175.7168 82 485.73 425.6200 1 167 $\tau^2 = 0.3342, p < 0.01$	44 379.52 26 71 254.38 5 115	9.7610 55.4200	-0.12 [-0.49; 0.24] 14.0 0.73 [0.40; 1.06] 14.4 0.31 [-5.12; 5.74] 28.4
Random effects mode Prediction interval Heterogeneity: $I^2 = 82\%$, Test for subgroup differen	1 442 $\tau^2 = 0.2210, p < 0.01$ nccs: $\chi^2_2 = 47.40, df = 2 (p < 1)$	362	-4 -2 0 2	0.50 [0.06; 0.94] 100.0 [-0.74; 1.74]

Figure 3b. Forest plot of NfL in bipolar disorder (age-matched studies only)

Figure 3a. Forest plot of NfL in bipolar disorder (all studies)

		Bipolar	disorder			Control	Standardised Mean			
Study	Total	Mean	SD	Total	Mean	SD	Difference	SMD	95%-CI	Weight
		Blood S	imoa							
Eratne et al. 2023	121	8.35	4.7600	96	9.36	14.1500	÷	-0.10	[-0.37; 0.17]	17.1%
Knorr et al. 2022	85	6.96	3.0920	44	6.04	2.5597		0.31	[-0.05; 0.68]	15.8%
Steinacker et al. 2021	11	21.20	16.6000	16	15.20	7.1000	-	0.49	[-0.29; 1.27]	10.1%
Al Shweiki et al. 2019	11	23.07	15.8767	27	17.08	8.7144		0.52	[-0.19; 1.24]	11.0%
Aggio et al. 2022	45	9.13	4.7800	29	4.28	2.3900	1 -	1.19	[0.69; 1.70]	13.8%
Random effects model	273			212			· ·	0.45	[-0.16; 1.06]	67.8%
Heterogeneity: $I^2 = 81\%$, τ	$^{2} = 0.19$	88, p < 0	.01							
		CSF ELI	SA							
Knorr et al. 2022	85	353.49	175.7168	44	379.52	269.7610		-0.12	[-0.49: 0.24]	15.8%
Rolstad et al. 2015	82	485.73	425.6200	71	254.38	55.4200		0.73	[0.40: 1.06]	16.3%
Random effects model	167			115				- 0.31	[-5.12: 5.74]	32.2%
Heterogeneity: $I^2 = 91\%$, τ	$^{2} = 0.33$	42, p < 0	.01						[•···_, •·· ·]	
Random effects model	440			327				0.40	[-0.04: 0.85]	100.0%
Prediction interval									I-0.80: 1.611	
Heterogeneity: $I^2 = 82\%$, τ	$^{2} = 0.18$	45. p < 0	.01						. ,	
Test for subgroup difference	ces: χ_1^2 =	= 0.09, df	= 1 (p = 0)	77)			-4 -2 0 2 4			

⁵⁶² Figure 3c. Forest plot of NfL in bipolar disorder (CSF and Simoa only)

Table 1. Characteristics of studies included: NfL in major depression

Authors and year	Country	Sample Type	Analysis type	Diagnosis classification	Mood state	Sample	e size	/ Mea	Age Mean (SD)		Sex male %)	NfL concentration^		Total NOS Score
						Case	Contro	Case	Control	Case	Control	Case	Control	
Ashton et al, 2021 (6)	England	Plasma	Simoa	DSM-5	Not specified	51	114	32.3 (6.9)	64.0 (14.1)	69%	55%	11.19 (5.8)	22.5 (10.7)	3
Bai et al, 2023 (43)	Taiwan	Serum	HRP ELISA	DSM-5	HDRS ≤16	24	29	30.8 (13.0)	30.9 (10.7)	67%	62%	22.4 (12.3)**	16.7 (6.8)	5
Bavato et al, 2021 (19)	Switzerland	Plasma	Simoa	DSM-5	Clinically stable	41	258	36.0 (10.9)	Unavailable	59%	NA%	26.3 (10.4)	24.5 (9.6)	5
Besse et al, 2020 (44)	Germany	Serum	Simoa	ICD-10	Moderate to severe depressive episode	15	15	49.2 (14.0)	"± 3 years"	73%	NA%	17.4 (11.88)	Mean = 15.57 95% CI*: 10.69, 20.40	5
Chen et al, 2022 (45)	Taiwan	Plasma	HRP ELISA	DSM-5	Not specified	40	40	28.3 (14.4)	28.3 (14.1)	68%	68%	28.8 (22.5)**	16.7 (8.1)	5
Eratne et al, 2023 (8)	Australia	Plasma	Simoa	DSM-IV	Depressive phase >= moderate severity	42	96	55.0 (12.9)	44.5 (14.4)	57%	52%	10.9 (7.0)**	9.4 (14.2)**	4
Gudmundsson et al, 2010 (14)	Sweden	CSF	ELISA Sandwich	DSM-III-R	Not specified	11	65	Combined: 7	73.9 (3.2)	100%	100%	427 (318)	277 (186)	5
Huang et al, 2023 (18)	Taiwan	Serum	Simoa	DSM-IV-TR	Outpatients	35	86	34.7 (10.3)	33.4 (6.2)	77%	13%	5.4 (2.2)	6.7 (2.7)	5
Hviid et al, 2023 (15)	Denmark	Serum	Simoa	DSM-IV	Treatment naive	110	33	42 (11)	39 (14)	65%	70%	7.7 (3.0)*	7.6 (3.1)*	5
Jiang et al 2021, (46)	China	Serum	ELISA Sandwich	DSM-IV	First episode, HDRS > 16	82	72	34 (11)	34 (12)	61%	49%	Median = 405.8 IQR: 281.5–625.5	Median = 143.5 IQR: 73.6–339.3	5
Katisko et al, 2020 (41)	Finland	Serum	Simoa	ICD-10	Included moderate, severe & psychotic depression	16	0	55.7 (6.7)	NA	56%	NA	12.4 (4.3)**	NA	3
Ramezani et al, 2022 (47)	Iran	Serum	ELISA	DSM-5	Suicide attempt	28	35	M: 26.28 (9.37) F: 26.61 (9.49)	M: 28.10 (8.54) F: 30.76 (5.12)	75%	71%	M: 55.42 (33.63) F: 36.66 (35.21)	M: 14.11 (4.38) F: 13.57 (5.45)	5
Steinacker et al, 2021 (17)	Germany	Serum	Simoa	DSM-5	Moderate-severe depressive episode	45	16	Median=48 Range 19-69	Median=45 Range 27-64	64%	75%	29.3 (35.3)	15.2 (7.1)	4
Wallensten et al, 2022 (48)	Sweden	Plasma	ELISA	ICD-10	Not specified	31	61	40.3 (10.8)	42.9 (9.5)	84%	85%	357.4 (87.1)	306.4 (115.7)	6

^CSF = ng/L, plasma/serum = pg/mL; *estimates using WebPlotDigitzer; **data obtained directly from corresponding author CI = confidence interval, F = females, HDRS = Hamilton Depression Rating Scale, M = males, MADRS = Montgomery-Asberg Depression Rating Scale, NA = not applicable, NOS = Newcastle-Ottawa Scale, YMRS = Young Mania Rating Scale

Table 2. Characteristics of studies included: NfL in bipolar disorder

Authors and year	Country	Sample Type	Analysis type	Diagnosis classification	Mood state	Sample size		Age Mean (SD)	Sex (Female %)		NfL conc		entration^	Total NOS Score
						Case	Control	Case	Control	Case	Control	Case	Control	
Aggio et al, 2022 (49)	Italy	Plasma	Simoa	DSM-IV	Depressed	45	29	48.2 (11.9)	41.8 (10.2)	78%	55%	9.1 (4.8)	4.28 (2.39)	3
Al Shweiki et al, 2019 (50)	Germany	Serum	Simoa	DSM-5	Manic, depressive and mixed states	11	27	Median = 51.4 IQR: 33.5-58.1	Median = 46.8 IQR: 39.1-54.1	36%	63%	Median = 17.8 IQR: 12.6 - 23.1	Median = 17.8 IQR: 11.3 - 19.1	4
Bai et al, 2023 (43)	Taiwan	Serum	HRP ELISA	DSM-5	YMRS ≤12	25	29	33.2 (13.2)	30.9 (10.7)	60%	62%	28.5 (12.4)**	16.7 (6.8)	5
Chen et al, 2022 (51)	Taiwan	Serum	Simoa	DSM-5	Euthymic	100		46.5 (11.7)	NA	52%	NA%	11.1 (8.1)**	NA	5
Eratne et al, 2023 (8)	Australia	Plasma	Simoa	DSM-IV	Depressive phase of at least moderate severity	121	96	44.1 (12.18)	44.48 (14.35)	62%	52%	8.4 (4.8)**	9.4 (14.2)**	5
Knorr et al, 2022 (16)	Denmark	CSF & Plasma	ELISA & Simoa	ICD-10	In remission (YMRS <=8; HDRS <= 8)	85	44	Median = 33 IQR: 26-42	Median = 30 IQR: 25-42	51%	52%	CSF: Median = 332 IQR: 246-479 Plasma: Median = 6.81 IQR: 4.97 - 9.07	CSF: Median = 354 IQR: 214-566 Plasma: Median = 5.73 IQR: 4.50 - 7.84	6
Ramezani et al, 2022 (47)	Iran	Serum	ELISA	DSM-5	Suicide attempt	22	35	M: 33.00 (15.18) F: 31.72 (13.10)	M: 28.10 (8.54) F: 30.76 (5.12)	82%	71%	M: 46.50 (38.27) F: 37.88 (31.63)	M: 14.11 (4.38) F: 13.57 (5.45)	5
Rolstad et al, 2015 (52)	Sweden	CSF	ELISA	DSM-IV	Euthymic (MADRS < 14, YMRS < 14)	82	71	38.3 (12.5)	37.8 (14.6)	59%	62%	485.7 (425.6)	254.4 (55.4)	5
Steinacker et al, 2021 (17)	Germany	Serum	Simoa	DSM-5	Manic, depressive and mixed states	11	16	Median = 48 Range: 19-69	Median = 45 Range: 27-64	27%	75%	21.2 (16.6)	15.2 (7.1)	4

^CSF = ng/L, plasma/serum = pg/mL; *estimates using WebPlotDigitzer; **data obtained directly from corresponding author CI = confidence interval, F = females, HDRS = Hamilton Depression Rating Scale, M = males, MADRS = Montgomery-Asberg Depression Rating Scale, NA = not applicable, NOS = Newcastle-Ottawa Scale, YMRS = Young Mania Rating Scale

Table 3. Characteristics of studies included: GFAP in major depression and bipolar disorder

Author	Country	Sample Type	Analysis type	Diagnosis classification	Mood state	Samp	ble size	Ag Mean	ge (SD)	So (Fema	ex ale %)	GFAP con	centration^	Total NOS Score
						Case	Control	Case	Control	Case	Control	Case	Control	
Major depressive disorder														
Gudmundsson et al, 2010 (14)	Sweden	CSF	ELISA Sandwich	DSM-III-R	Not specified	11	65	Cases + contr	ols: 73.9 (3.2)	100%	100%	946 (196)	887 (308)	5
Hviid et al, 2023 (15)	Denmark	Serum	Simoa	DSM-IV	Treatment naïve	110	33	42 (11)	39 (14)	65%	70%	63.7 (23.8)*	74.2 (35.2)*	5
Katisko et al, 2021 (42)	Finland	Serum	Simoa	ICD-10	Included moderate, severe and psychotic depression	22	0	55.7 (6.3)	NA	55%	NA	224 (113)**	NA	3
Michel et al, 2021 (20)	Germany	CSF	ELISA	ICD-10	Inpatients	102	39	44.2 (13.6)	34.6 (12.0)	54%	85%	733 (401)	245.6 (176.3)	5
Steinacker et al, 2021 (17)	Germany	Serum	Simoa	DSM-5	Moderate- severe depressive episode	45	16	Median = 48 Range 19-69	Median = 45 Range 27-64	64%	75%	211 (99)	147.0 (61.0)	4
Bipolar disorder														
Steinacker et al, 2021 (17)	Germany	Serum	Simoa	DSM-5	Manic, depressive and mixed states	11	16	Median = 48 Range 19-69	Median = 45 Range 27-64	27%	75%	125 (50)	147.0 (61.0)	4

 $^{CSF} = ng/L$, plasma/serum = pg/mL; *estimates using WebPlotDigitzer; **unpublished data obtained directly from corresponding author F = females, M = males, NA = not applicable, NOS = Newcastle-Ottawa Scale

eMethods - Search strategy for respective databases

Database: Ovid MEDLINE(R): inception to June 27, 2023

Search Strategy:

1. Affective Symptoms/ or exp Catatonia/ or exp Depression/ or exp Mental Fatigue/ or exp Mood Disorders/ or exp Anxiety/ or exp Anxiety Disorders/ or Mania/ or Depression, Chemical/ or Cognitive Dysfunction/ or depress*.mp. or bipolar*.mp. or anxiety*.mp. or *Mental Disorders/ or psychiatric disorder*.mp. (1080981)

2. Glial Fibrillary Acidic Protein/ or Neurofilament Proteins/ (22084)

3. (neurofilament light* or glial fibrillary acidic protein*).mp. (27935)

4. 2 or 3 (32209)

5. 1 and 4 (1445)

6. (5 not rats not animals/) or (5 and humans/) (656)

Database: Web of Science Search Strategy: inception to June 27, 2023

Searches:

1: TS=(bipolar*) OR TS=(mania*) OR TS=(depressi*) OR TS=(anxiety*) OR TS=(psychiatr* disord*) OR TS=(mental disorder*) 1230138

2: TS=(neurofilament*) OR TS=(Glial fibrillary acidic protein*) OR TS=(NF-L) OR TS=(GFAP) 40397

3: #1 AND #2 and Article or Early Access or Proceeding Paper or Data Paper or Note or Letter (Document Types) 1554

Embase search: inception to May 31 2023

1. exp glial fibrillary acidic protein/ 36983

2 exp neurofilament/ or exp neurofilament protein/ 19626 medRxiv Preprint doi: https://doi.org/10.1401/2024.03.07.24303938; this version posted March 9, 2024. The copyright holder for this preprint (whick pack opression) or perpendicular discorder/fundee 6/hb has granted medRxiv a license to display the preprint in perpetuity. 4. exp bipolar depression/ or exp bipolar discorder/ or exp manua/ 96498

5. exp anxiety/ or exp anxiety assessment/ or exp anxiety disorder/ 611058

6. 1 or 2 53764

7. 3 or 4 or 5 1070529

8. 6 and 7 1554

9. limit 8 to human 809

Pubmed: inception to May 31 2023

((bipolar* OR depress* OR anxie*)) AND (neurofilament light* OR glial fibrillary acidic protein*) 1059 hits

PSYCHInfo: Inception to May 31 2023

(Neurofilaments or neurofilament protein L or Neurofilament Proteins or Glial Fibrillary Acidic Protein or (neurofilament light* or glial 1 fibrillary acidic protein*)).mp. (4714)

exp Chronic Fatigue Syndrome/ or exp Chronic Mental Illness/ or exp Affective Disorders/ or exp Anxiety Disorders/ or exp Bipolar 2 Disorder/ or exp Chronic Mental Illness/ or exp Affective Psychosis/ or exp Acute Stress Disorder/ or exp Adjustment Disorders/ or exp Prolonged Grief Disorder/ or exp Fatigue/ or exp Psychiatric Symptoms/ or exp Treatment Resistant Disorders/ or exp Treatment Resistant Depression/ or exp Atypical Depression/ or exp Acute Stress Disorder/ or depress*.mp. or bipolar*.mp. or anxiety*.mp. or psychiatric disorder*.mp. or mental disorder*.mp. (779119)

3 1 and 2 (372)

> 4 limit 7 to human (150)

Study Author	Selection - Representativeness of the cohort - Sample size justification - Ascertainment of mood or anxiety disorder	Comparability - Controls for age between case and controls - Controls for additional covariates (sex, weight, BMI, renal function) between cases and controls	Outcome - Validated measure of biomarker - Appropriate statistical analysis which is well described	Total
Aggio et al, 2022 (1)	1	0	2	3
<i>Al Shweiki et al, 2019</i> (2)	1	1	2	4
Ashton et al, 2021 (3)	1	0	2	3
Bai et al, 2023 (4)	1	2	2	5
Bavato et al, 2021 (5)	1	2	2	5
Besse et al, 2020 (6)	1	2	2	5
<i>Chen et al, 2022b (7)</i>	1	2	2	5
<i>Chen et al. 2022a (8)</i>	1	2	2	5
medRxiv preprint doi: https://doi.org/10.1 (which and coet atting the performance of the	101/2024.03.07.24303938; this version po iew) is the author/funder, who has granted made available under a CC-BY-ND 4.0 In	osted March 9, 2024. The copyright holder for this preprind medRxiv a license to display the preprint in perpetuity. International license.	t 2	5
Eratne et al, 2023 (9) (depression)	1	1	2	4
Gudmundsson et al, 2010 (10)	1	2	2	5
Huang et al, 2023 (11)	1	2	2	5
Hviid et al. 2023 (12)	1	2	2	5
Jiang et al 2021, (13)	1	2	2	5
Katisko et al, 2020 (14)	1	0	2	3
Katisko et al, 2021 (15)	1	0	2	3
Knorr et al, 2022 (16)	3	2	1	6
Michel et al, 2021 (17)	1	2	2	5
Ramezani et al, 2022 (18)	1	2	2	5
Rolstad et al, 2015 (19)	1	2	2	5
Steinacker et al, 2021 (20)	1	1	2	4
Wallensten et al, 2022 (21)	2	2	2	6

eReferences

1. Aggio V, Fabbella L, Finardi A, Mazza EB, Colombo C, Falini A, et al. Neurofilaments light: Possible biomarker of brain modifications in bipolar disorder. Journal of Affective Disorders. 2022 Mar;300:243–8.

- Al Shweiki MR, Steinacker P, Oeckl P, Hengerer B, Danek A, Fassbender K, et al. Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. Journal of Psychiatric Research. 2019;113(February):137–40.
- 3. Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021 Jun 7;12(1):3400.
- 4. Bai YM, Liu YL, Kuo HW, Tsai SJ, Hsu JW, Huang KL, et al. Procollagen type 1 N-terminal propeptide, neurofilament light chain, proinflammatory cytokines, and cognitive function in bipolar and major depressive disorders: An exploratory study of brain– bone axis and systemic inflammation. Journal of Psychiatric Research. 2023 Feb;158:403–8.
- 5. Bavato F, Cathomas F, Klaus F, Gütter K, Barro C, Maceski A, et al. Altered neuroaxonal integrity in schizophrenia and major depressive disorder assessed with neurofilament light chain in serum. Journal of Psychiatric Research. 2021 Aug;140:141–8.
- 6. Besse M, Belz M, Folsche T, Vogelgsang J, Methfessel I, Steinacker P, et al. Serum neurofilament light chain (NFL) remains unchanged during electroconvulsive therapy. The World Journal of Biological Psychiatry. 2020 Feb 7;21(2):148–54.
- 7. Chen WY, Huang MC, Chiu CC, Cheng YC, Kuo CJ, Chen PY, et al. The interactions between vitamin D and neurofilament light chain levels on cognitive domains in bipolar disorder. BJPsych open. 2022 Nov;8(6):e207.

- 8. Chen MH, Liu YL, Kuo HW, Tsai SJ, Hsu JW, Huang KL, et al. Neurofilament light chain is a novel biomarker for major depression and related executive dysfunction. International Journal of Neuropsychopharmacology. 2022;25(2):99–105.
- 9. Eratne D, Kang M, Malpas C, Simpson-Yap S, Lewis C, Dang C, et al. Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disorders. Aust N Z J Psychiatry. 2023 Jul 21;00048674231187312.
- 10. Gudmundsson P, Skoog I, Waern M, Blennow K, Zetterberg H, Rosengren L, et al. Is there a CSF biomarker profile related to depression in elderly women? Psychiatry Research. 2010;176(2-3):174-8.
- 11. Huang MC, Chen CH, Liu TH, Chung AN, Liu YL, Quednow BB, et al. Comorbidity of ketamine dependence with major depressive disorder increases the vulnerability to neuroaxonal pathology. Journal of Psychiatric Research. 2023 Feb;158:360–4.
- 12. Hviid CVB, Benros ME, Krogh J, Nordentoft M, Christensen SH. Serum glial fibrillary acidic protein and neurofilament light chain in treatment-naïve patients with unipolar depression. Journal of Affective Disorders. 2023 Oct 1;338:341-8.
- 13. Jiang L, Shen Z, Cheng Y, Lu J, He B, Xu J, et al. Elevated serum neurofilament levels in young first-episode and medication-naïve major depressive disorder patients with alterative white matter integrity. Psychiatry Research: Neuroimaging. 2021 Nov;317:111351.
- 14. Katisko K, Cajanus A, Jääskeläinen O, Kontkanen A, Hartikainen P, Korhonen VE, et al. Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders. J Neurol. 2020 Jan;267(1):162-7.
- 15. Katisko K, Cajanus A, Huber N, Jääskeläinen O, Kokkola T, Kärkkäinen V, et al. GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance. | Neurol Neurosurg Psychiatry. 2021 Dec;92(12):1305–12.
- medRxiv preprint doi: https://doi.org/10.1101/2024.03.07.24303938; this version posted March 9, 2024. The copyright holder for this preprint (Mich Knoppt Up Simon seer Ally Veisser (Conternal gradient and the mode and the mode of the second disorder and the second disor
 - 17. Michel M, Fiebich BL, Kuzior H, Meixensberger S, Berger B, Maier S, et al. Increased GFAP concentrations in the cerebrospinal fluid of patients with unipolar depression. Transl Psychiatry. 2021 Jun;11(1):308.
 - 18. Ramezani M, Simani L, Fard MG, Abbaszadeh F, Shadnia S. Increased levels of neurofilament light chain in suicide attempters' serum. Translational Neuroscience. 2022 Aug 5;13(1):218-23.
 - 19. Rolstad S, Jakobsson J, Sellgren C, Ekman CJ, Blennow K, Zetterberg H, et al. Cognitive performance and cerebrospinal fluid biomarkers of neurodegeneration: a study of patients with bipolar disorder and healthy controls. PloS one. 2015;10(5):e0127100e0127100.
 - 20. Steinacker P, Al Shweiki MR, Oeckl P, Graf H, Ludolph AC, Schönfeldt-Lecuona C, et al. Glial fibrillary acidic protein as blood biomarker for differential diagnosis and severity of major depressive disorder. Journal of Psychiatric Research. 2021 Dec;144:54-8.
 - 21. Wallensten J, Mobarrez F, Åsberg M, Borg K, Beser A, Wilczek A, et al. Plasma levels of S100B and neurofilament light chain protein in stress-related mental disorders. Sci Rep. 2022 May 18;12(1):8339.

sFigure 1 - Funnel plots

a. NfL in major depression









Standardised Mean Difference

medRxiv preprint doi: https://doi.org/10.1101/2024.03.07.24303938; this version posted March 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.



PRISMA 2020 Checklist

Section and Topic	ltem #	Checklist item	Location where item is reported
TITLE			
d Title	1	Identify the report as a systematic review.	Pg 1
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Pg 4-5
	0		
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Pg 6/line 89
	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Pg 7/line 133
	F	Creatify the inclusion and evolution evitaria for the review and have studies were ground for the surtheses	Dg 7/lipo 144
	5	Specify the inclusion and exclusion criteria for the review and now studies were grouped for the syntheses.	Pg //iine 144
	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Pg 8/line 156
earch strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Supplementar
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Pg 8/line 164
a Data collection त्र Orocess	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Pg 8/line 171
Depata items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Pg 8/line 171
vailabl	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Pg 8/line 171
g gessessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Pg 9/line 185
.€ffect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Pg 8/line 171
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Pg 7/line 186
ed by	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Pg 8/line 173
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Pg 9/line 182
not ce	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Pg 9/line 182
Nas	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	Pg 9/line 205
C L L L L L L L L L L L L L L L L L L L	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Pg 9/line 205
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	Pg 10/line 221
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	Pg 9/line 201



PRISMA 2020 Checklist

ler for thi	Section and Topic	ltem #	Checklist item	Location where item is reported			
holo	RESULTS						
yright , the n	Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Figure 1			
cop		16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Pg 10/line 233			
4. The	Study characteristics	17	Cite each included study and present its characteristics.	Table 1-2			
9, 202 license	Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Supplementary eTable 1			
March Rxiv a	Results of	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Pg 11/line 264 Figures 2-3			
med	Results of	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Supplementary			
on pos	ăyntheses 0. 4	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Pg 11/line 263			
ersi s or	QN	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Pg 11/line 267			
ha v	₽	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Pg 11/line 73			
×,±	Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Supplementary			
130390 funder	Certainty of	22	22 Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.				
7.2							
03.0 Autl	de ade ade ade ade ade ade ade ade ade a	23a	Provide a general interpretation of the results in the context of other evidence.	Pg 13/line 320			
124.(23b	Discuss any limitations of the evidence included in the review.	Pg 14/line 355			
1/2(si		23c	Discuss any limitations of the review processes used.	Pg 14/line 360			
110 viev	m s	23d	Discuss implications of the results for practice, policy, and future research.	Pg 15/line 368			
70. 10.	*OTHER INFORMA	TION					
org	Registration and	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Pg 7/line 143			
	protocor	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Pg 7/line 143			
tps:/		24c	Describe and explain any amendments to information provided at registration or in the protocol.	N/A			
t te	Support	25 Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.		Pg 2/line 14			
rint do	Competing interests	26 Declare any competing interests of review authors.		Pg 2/line 25			
Rxiv prep	Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	N/A			

medR d

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71 Pg 8/line 193